Anupam Rasayan India Ltd — earnings calls

Anupam Rasayan reported Q1 FY27 consolidated total income of Rs 668 crore, up 36% year-on-year, with EBITDA up 35% to Rs 175 crore and margins at 26%, while PAT grew 6% to Rs 51 crore due to higher depreciation. Management highlighted the commercialization of ETFA using flow chemistry, a Letter of Intent with BASQUEVOLT worth approximately USD 300 million over 10 years, and progress on the Jayhawk integration and the pending Bliss GVS Pharma acquisition. Management described Jayhawk's contribution at around 20-22% of quarterly revenue with EBITDA margins of 19-20%, and said the Bliss transaction is expected to close in the first half of September.

Anupam Rasayan reported its highest ever annual revenue for FY26, with consolidated revenue from operations at INR2,384 crores, up 65% year-on-year, and EBITDA margin of 23%. The company completed the acquisition of Jayhawk Fine Chemicals and announced a definitive agreement to acquire a 43.3% to 48.2% equity stake in Bliss GVS Pharma along with an open offer for up to 26% additional shares. Management described diversification away from agrochemicals, with pharma revenue growing to INR339 crores in FY26 from INR21 crores in FY22, and outlined plans to integrate Tanfac, Jayhawk and Bliss GVS Pharma into its platform strategy.